An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved medical prostate cancer vaccine, Provenge, is innocuous and has few position effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both safeness and clinical data," said head researcher Dr Simon J Hall, chairman of urology at Mount Sinai Medical Center in New York City.

This sanctuary data shows that there are very limited side effects. The gain of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side slang shit than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.

The ordinary survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly close by treatment, with very limited surface effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual assignation in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved supremacy of freshness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.

In terms of viewpoint effects, the most common were flu-like symptoms such as chills, fever and headache, which were seen in 3,5 percent of the men. Usually it took only a broad daylight or two for the symptoms to resolve. More serious side effects, such as infusion reactions, counterfeit 3,5 percent of the patients. Cerebrovascular problems affected 3,5 percent of those who received the vaccine and 2,6 percent of those who received placebo, Hall's order found.

Dr Nelson Neal Stone, a clinical professor of urology and emission oncology at Mount Sinai School of Medicine in New York City, said that "the squad effects are have a weakness for having the flu and they can be managed with aspirin". However, Stone pointed to one big drawback to Provenge: cost. "I've heard $30000, I've heard $90000. I have no phantasy what it's common to cost. And who's going to pay for it?" he said.

Provenge is a therapeutic (not preventive) vaccine that is made from the patient's own snowy blood cells. Once removed from the patient, the cells are treated with the cure-all and placed back into the patient. These treated cells then cause an immune response, which in put kills cancer cells, while leaving normal cells unharmed. According to the FDA, Provenge is given intravenously in a three-dose record delivered in two-week intervals.

The vaccine was developed by Seattle-based Dendreon Corp, which conducted endorse studies among men with advanced prostate cancer who had already failed law hormone treatment. According to American Cancer Society estimates, more than 192000 experimental cases of prostate cancer are diagnosed in the United States each year, and 27360 men go for a burton from the disease.

Prostate cancer is the most common form of cancer diagnosed in American men, after husk cancer. More than 2 million American men who have had prostate cancer at some point are still astir today karachi sxsy anti. The death rate is going down and the disease is being found earlier, according to the cancer society.